Observational study of serum HER2 in HER2 positive advanced gastric cancer treated with trastuzumab in combination with capecitabine plus cisplatin(XP+H)

Trial Profile

Observational study of serum HER2 in HER2 positive advanced gastric cancer treated with trastuzumab in combination with capecitabine plus cisplatin(XP+H)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Trastuzumab
  • Indications Gastric cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms SHERLOCK2
  • Most Recent Events

    • 01 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top